Streetbeat News

MRK

Merck & Co., Inc.

https://www.merck.com

Industry

Drug Manufacturers - General

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Open

101.13

Mkt cap

258B

Volume

7.5M

High

102.57

P/E Ratio

21.34

52-wk high

134.63

Low

100.53

Div yield

0.02

52-wk low

94.48

Merck has announced positive topline results from two Phase 3 trials of V116, an investigational 21-valent pneumococcal conjugate vaccine. The trials demonstrated immune responses in both vaccine-naïve and vaccine-experienced adult patient populations.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 10:47 am

Merck & Co Inc and Moderna Inc have initiated a Phase 3 trial for V940 (mRNA-4157), a personalized skin cancer therapy. The trial will enroll approximately 1,089 patients, with the first patients now enrolling in Australia. The therapy has been granted Breakthrough Therapy Designation by the FDA and the Priority Medicines scheme by the European Medicines Agency. The companies also plan to expand the development program to additional tumor types.

Portfolio Pulse from Vandana Singh

July 26, 2023 | 4:04 pm

Merck and Moderna have initiated a Phase 3 study evaluating V940 (mRNA-4157) in combination with KEYTRUDA for adjuvant treatment of patients with resected high-risk melanoma. The first patients are now enrolling in Australia.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 10:51 am

Cathie Wood's Ark Investment Management has increased its stake in Moderna, Inc. (NASDAQ:MRNA) by $12M this week, ahead of the company's Q2 results. The purchases were made through Ark Genomic Revolution ETF (CBOE: ARKG), which now holds 244,271 shares of Moderna, accounting for 1.26% of the portfolio. Moderna is expected to report a loss of $4.03 per share, a significant reversal from a profit of $5.24 in the year-ago period. The company is also developing a personalized cancer vaccine with Merck & Co., Inc. (NYSE:MRK).

Portfolio Pulse from Shanthi Rexaline

July 26, 2023 | 6:47 am

Russia has been seizing assets from Western companies, including Danone and Carlsberg. In response, many foreign companies are planning to leave Russia or reduce their operations there. Several US companies, including Ford, IBM, McDonalds, Delta Airlines, Nike, United Airlines, Starbucks, Hewlett Packard, Uber, Netflix, American Airlines, and Dell, have announced a full retreat from the country. However, other US companies like Cloudflare, Tupperware, Procter & Gamble, Colgate-Palmolive, Kimberly Clark, Abbott Laboratories, Pfizer, Merck, Johnson and Johnson, Eli Lilly, Philip Morris, Coca-Cola, PepsiCo, Kellogg's, General Electric, Whirlpool, John Deere, FedEx, UPS, Intel, Qualcomm, Micron, Nvidia, and Apple continue to operate in Russia, albeit with reduced operations or suspended investments.

Portfolio Pulse from Natan Ponieman

July 24, 2023 | 8:45 pm

HC Wainwright analyst Robert Burns has lowered the price target for Nurix Therapeutics Inc (NRIX) from $53 to $33, citing higher operating expenses and a decrease in the terminal growth rate. This comes after Nurix presented clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127. The analysts also compared Nurix's results with Merck & Co Inc's (MRK) BELLWAVE-001 trial results, noting that nemtabrutinib's response rate is highly encouraging.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 6:14 pm

William Blair initiated coverage on Moderna Inc (MRNA) with a Market Perform rating, establishing a fair value estimate of $136.28 per share. The valuation considers the declining COVID-19 base business, the competitive ex-COVID vaccine landscape, and the timing gap to the early-stage therapeutic pipeline. The firm models around $6.3 billion in global COVID-19 vaccine revenue in 2023. Moderna's personalized cancer vaccine (PCV), developed in partnership with Merck & Co Inc (MRK), has shown positive results in Phase 2 trials and is advancing to Phase 3.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 3:39 pm

The Dow Jones Industrial Average (DJIA) marked its tenth consecutive positive session, the longest winning streak since February 2017. The SPDR Dow Jones Industrial Average ETF (DIA) closed 0.09% lower, ending its winning streak. Top performers in the Dow Jones were Merck & Company (MRK), Procter & Gamble (PG), and Chevron Corp. (CVX). Laggards included Microsoft Corp. (MSFT), American Express Company (AXP), and Caterpillar Inc. (CAT). Traders are awaiting the Federal Open Market Committee Meeting, with a 0.25% rate hike already factored in.

Portfolio Pulse from Piero Cingari

July 21, 2023 | 8:29 pm

Merck (NYSE:MRK) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for gefapixant, a non-narcotic oral selective P2X3 receptor antagonist developed for the treatment of adults with chronic cough. The recommendation will be reviewed by the European Commission for marketing authorization in the EU, with a final decision expected later this year.

Portfolio Pulse from Charles Gross

July 21, 2023 | 11:53 am

A large bearish position has been taken on Merck & Co (NYSE:MRK), with 12 uncommon options trades spotted. The sentiment of these big-money traders is split between 41% bullish and 58% bearish. Whales have been targeting a price range from $45.0 to $130.0 for Merck & Co over the last 3 months. Truist Securities maintains a Buy rating on Merck & Co with a price target of $116, while HSBC and Morgan Stanley have downgraded their actions with price targets of $123 and $109 respectively.

Portfolio Pulse from Benzinga Insights

July 20, 2023 | 7:46 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.